# Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF

> **NCT03794518** · PHASE3 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 648 (estimated)

## Conditions studied

- Risk Reduction

## Interventions

- **DRUG:** Pioglitazone Plus dapaglifliozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03794518
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03
- **Primary completion:** 2021-09
- **Final completion:** 2021-12
- **Target enrollment:** 648 (ESTIMATED)
- **Last updated:** 2019-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794518, "Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03794518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*